Tarsus Pharmaceuticals, Inc.
TARS
Classifica tra le azioni
#4648
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Prezzo delle azioni
$69.68
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$3.26B
Variazione (1 giorno)
2.36%
Variazione (1 anno)
-2.13%
Paese
US
Scambia Tarsus Pharmaceuticals, Inc. (TARS)
Categoria
Healthcare
Rapporto P/S per Tarsus Pharmaceuticals, Inc. (TARS)
Rapporto P/S al October 2026 TTM: 5.13
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Tarsus Pharmaceuticals, Inc., il rapporto P/S attuale (TTM) è 5.13. Alla fine del 2023, era pari a 34.10.
Storico del rapporto P/S per Tarsus Pharmaceuticals, Inc. da 2018 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 5.13 | -54.93% |
| 2024 | 11.38 | -66.63% |
| 2023 | 34.10 | 143.94% |
| 2022 | 13.98 | 72.40% |
| 2021 | 8.11 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 10.02 | 95.38% |
US
|
|
| 40.55 | 690.54% |
US
|
|
| 3.96 | -22.78% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 97.80% |
NL
|
